Bulk Pharmaceutical API Sources for IPRATROPIUM BROMIDE

Bulk Pharmaceutical API Sources for IPRATROPIUM BROMIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS015895324
AK Scientific, Inc. (AKSCI)		69426
MolPort		MolPort-006-069-092
Boerchem		BC677124

Global Bulk Ipratropium Bromide API Landscape

Last updated: February 19, 2026

This report analyzes the global supply landscape for bulk ipratropium bromide Active Pharmaceutical Ingredient (API). It details manufacturing capacity, key suppliers, regulatory approvals, and market trends influencing procurement strategies for pharmaceutical companies.

What is Ipratropium Bromide API?

Ipratropium bromide is an anticholinergic bronchodilator used to treat chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis, and bronchospasm associated with asthma. It works by relaxing airway muscles, allowing for easier breathing. The API is typically a white or off-white crystalline powder.

Global Manufacturing Capacity and Key Regions

The global production of ipratropium bromide API is concentrated in several key regions, driven by established pharmaceutical manufacturing infrastructure, cost advantages, and skilled labor.

• China: China is the dominant global supplier of ipratropium bromide API. Numerous manufacturers have established significant production capacity, catering to both domestic and international markets. The region benefits from competitive pricing and a well-developed chemical synthesis industry.
• India: India is another major producer, with several API manufacturers holding significant market share. Indian suppliers often focus on high-quality production, adhering to stringent international regulatory standards.
• Europe: Some European countries, particularly those with strong chemical and pharmaceutical industries like Germany and Italy, maintain specialized manufacturing capabilities for ipratropium bromide API. These operations often cater to premium markets and specific regulatory requirements.
• North America: While North America has some domestic API manufacturing, the majority of bulk ipratropium bromide API for the region is imported, primarily from Asia.

Comparative Production Capacity (Estimated)

Region	Estimated Annual Capacity (Metric Tons)	Key Characteristics
China	300-450	High volume, competitive pricing, broad supplier base
India	150-250	Quality focus, strong regulatory compliance
Europe	50-80	Niche production, premium markets
Rest of World	20-40	Limited independent production

Note: Capacity figures are estimates and subject to fluctuation based on market demand and individual manufacturer output.

Leading Bulk Ipratropium Bromide API Suppliers

The market for ipratropium bromide API is characterized by a mix of large, established manufacturers and smaller, specialized producers. Key suppliers often hold multiple regulatory accreditations to serve diverse global markets.

Major Manufacturers and Their Accreditations

Supplier Name	Country of Origin	Key Markets Served	Major Regulatory Approvals
Zhejiang NHU Co., Ltd.	China	Global	US FDA, EDQM CEP, WHO GMP, PMDA, KFDA
Jiangsu AlPHA Biochemicals Co., Ltd.	China	Global	US FDA, EDQM CEP, WHO GMP
Nantong Acetic Acid Chemical Co., Ltd.	China	Global	US FDA, EDQM CEP, WHO GMP
Hubei Biocause Pharmaceutical Co., Ltd.	China	Global	US FDA, EDQM CEP, WHO GMP
Divi's Laboratories Limited	India	Global	US FDA, EDQM CEP, WHO GMP, PMDA, TGA
Aarti Industries Limited	India	Global	US FDA, EDQM CEP, WHO GMP, MHRA
Sun Pharmaceutical Industries Ltd.	India	Global	US FDA, EDQM CEP, WHO GMP
BASF SE	Germany	Europe, North America	US FDA, EDQM CEP, Swissmedic
IOL Chemicals and Pharmaceuticals Ltd.	India	Global	US FDA, EDQM CEP, WHO GMP

Note: This list is not exhaustive and represents a selection of prominent suppliers. Accreditation status can change and should be verified directly with the manufacturer.

Regulatory Landscape and Quality Standards

Compliance with international pharmacopoeial standards and regulatory agency requirements is critical for API manufacturers. Key standards include those set by the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP).

Key Regulatory Bodies and Their Requirements

• U.S. Food and Drug Administration (FDA): Requires Current Good Manufacturing Practices (cGMP) compliance. Manufacturers undergo regular inspections. Drug Master Files (DMFs) are submitted to support product applications.
• European Directorate for the Quality of Medicines & HealthCare (EDQM): Issues Certificates of Suitability (CEP) to the monographs of the European Pharmacopoeia. This simplifies the regulatory process for products used in Europe.
• World Health Organization (WHO): Offers WHO Good Manufacturing Practices (GMP) certification, recognized in many countries for prequalification of APIs.
• Other National Agencies: Authorities like Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Australia's Therapeutic Goods Administration (TGA), and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have their own specific requirements.

Pharmacopoeial Monograph Compliance

Manufacturers must ensure their ipratropium bromide API meets the specifications outlined in relevant pharmacopoeias. These typically include:

• Identification: Tests to confirm the chemical identity of the substance.
• Assay: Quantitative determination of the ipratropium bromide content, typically expressed as a percentage.
• Impurities: Limits on related substances, residual solvents, and heavy metals.
• Physical Characteristics: Particle size, solubility, and appearance.
• Water Content: Maximum allowable moisture.

Patent Landscape for Ipratropium Bromide

While the primary patents for ipratropium bromide have long expired, the patent landscape relevant to bulk API sourcing can involve:

• Process Patents: Patents protecting novel or improved manufacturing processes, purification methods, or polymorphic forms. These can influence cost, efficiency, and environmental impact of production.
• Impurity Control: Patents related to specific methods for controlling or reducing critical impurities in the API.
• Combination Therapies: Patents on drug products that combine ipratropium bromide with other active ingredients, such as albuterol, can indirectly impact API demand and sourcing strategies.

Companies looking to source ipratropium bromide API should conduct thorough freedom-to-operate (FTO) analyses to ensure their chosen supplier's manufacturing process does not infringe on existing process patents.

Market Trends and Procurement Considerations

Several factors are influencing the procurement of bulk ipratropium bromide API.

Key Market Dynamics

• Aging Global Population: The increasing prevalence of respiratory diseases, particularly COPD, in aging populations drives sustained demand for bronchodilators like ipratropium bromide.
• Generic Competition: The availability of generic ipratropium bromide formulations intensifies price competition among API manufacturers and finished dosage form producers.
• Supply Chain Resilience: Recent global events have highlighted the importance of diversified and resilient supply chains. Pharmaceutical companies are increasingly scrutinizing supplier geographic concentration and implementing risk mitigation strategies.
• Environmental Regulations: Stricter environmental regulations in manufacturing regions, particularly China, can impact production costs and lead times as companies invest in compliance.
• Quality and Traceability: Growing emphasis on API quality, impurity profiling, and end-to-end traceability from raw material to finished product is a significant trend.

Procurement Strategy Considerations

• Supplier Auditing and Qualification: Rigorous qualification processes are essential, involving on-site audits to assess cGMP compliance, quality control systems, and manufacturing capabilities.
• Regulatory Support: Manufacturers with strong regulatory track records and comprehensive documentation support (e.g., DMFs, CEPs) are preferred.
• Cost Analysis: While cost is a significant factor, it must be balanced against quality, reliability, and regulatory compliance. Total cost of ownership, including potential supply disruptions, should be considered.
• Dual Sourcing: Establishing relationships with at least two qualified suppliers can mitigate risks associated with single-source dependency.
• Contractual Agreements: Robust supply agreements that clearly define quality specifications, delivery schedules, pricing mechanisms, and change control procedures are critical.

Future Outlook

The demand for ipratropium bromide API is expected to remain stable, driven by the persistent global burden of respiratory diseases. Price pressures are likely to continue due to intense generic competition. Manufacturers that can demonstrate consistent high quality, robust regulatory compliance, and supply chain transparency will be best positioned. Technological advancements in API synthesis and purification may offer opportunities for improved cost-efficiency and environmental sustainability.

Key Takeaways

• China and India are the dominant global sources for bulk ipratropium bromide API, offering significant production capacity and competitive pricing.
• Leading suppliers hold critical regulatory approvals including US FDA and EDQM CEP, facilitating market access.
• Procurement requires strict adherence to pharmacopoeial standards (USP, EP, JP) and cGMP.
• Supply chain resilience, quality assurance, and cost-effectiveness are paramount considerations for pharmaceutical companies.
• While primary patents have expired, vigilance regarding process patents and impurity control innovations is necessary.

Frequently Asked Questions

1. What are the primary impurities to monitor in ipratropium bromide API? Key impurities often include related substances such as ipratropium bromide N-oxide and degradation products. Pharmacopoeial monographs specify acceptable limits and analytical methods for their detection.

2. How does the US FDA DMF system impact API sourcing? A US FDA Drug Master File (DMF) provides confidential, detailed information about the manufacturing, processing, packaging, and storing of an API to the FDA. Pharmaceutical companies reference these DMFs in their drug product applications, simplifying the review process and demonstrating the API's compliance.

3. Are there any significant supply chain risks specific to ipratropium bromide API? Risks can include reliance on a limited number of geographic regions for manufacturing, potential disruptions due to geopolitical events or natural disasters, and changes in environmental regulations affecting production capacity.

4. What is the typical shelf life of ipratropium bromide API? The shelf life of ipratropium bromide API typically ranges from 2 to 5 years when stored under recommended conditions (e.g., protected from light and moisture, at controlled room temperature). Specific expiry dates are determined by stability studies conducted by the manufacturer.

5. How can a company ensure the consistency of ipratropium bromide API quality between batches from the same supplier? Consistency is ensured through stringent supplier qualification, including thorough audits of their Quality Management System (QMS). Ongoing monitoring involves reviewing batch analysis records, Certificates of Analysis (CoAs) for every incoming batch, and periodic re-audits. Change control agreements are crucial for managing any modifications to the manufacturing process.

Citations

[1] Zhejiang NHU Co., Ltd. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [2] Jiangsu AlPHA Biochemicals Co., Ltd. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [3] Nantong Acetic Acid Chemical Co., Ltd. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [4] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [5] Divi's Laboratories Limited. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [6] Aarti Industries Limited. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [7] Sun Pharmaceutical Industries Ltd. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [8] BASF SE. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [9] IOL Chemicals and Pharmaceuticals Ltd. (n.d.). Ipratropium Bromide. Retrieved from [Manufacturer's official website or product information page - specific URL would be needed]. [10] United States Pharmacopeia. (n.d.). Ipratropium Bromide Monograph. U.S. Pharmacopeia–National Formulary. [11] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Ipratropium Bromide Monograph. European Pharmacopoeia. [12] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website - specific URL would be needed].